Silence Therapeutics reports Q1 EPS (11c) vs. (20c) last year

Reports revenue $422,000 vs. $142,000 last year, “The Silence team continues to advance research supporting the broad potential of our mRNAi GOLD platform, and we remain well positioned as we approach a significant company milestone,” said Iain Ross, Chairman and Interim Principal Executive Officer at Silence. “With Phase 2 topline results in PV expected this August, our team remains focused on progressing divesiran and delivering long-term value for patients and shareholders.”